Advanced search
Publication Cover
Hematology Volume 24, 2019 - Issue 1
Submit an article Journal homepage
2,083
Views
28
CrossRef citations to date
0
Altmetric
Articles

Soluble programmed death-ligand 1 are highly expressed in peripheral T-cell lymphoma: a biomarker for prognosis

Haorui ShenDepartment of Hematology, Peking Union Medical College Hospital, Beijing, People’s Republic of ChinaView further author information
,
Yali JiDepartment of Hematology, Peking Union Medical College Hospital, Beijing, People’s Republic of ChinaView further author information
,
Daobin ZhouDepartment of Hematology, Peking Union Medical College Hospital, Beijing, People’s Republic of ChinaView further author information
,
Yan ZhangDepartment of Hematology, Peking Union Medical College Hospital, Beijing, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0003-0244-218XView further author information
ORCID Icon,
Wei WangDepartment of Hematology, Peking Union Medical College Hospital, Beijing, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-1192-4896View further author information
ORCID Icon,
Jian SunDepartment of Pathology, Peking Union Medical College Hospital, Beijing, People’s Republic of ChinaView further author information
&
Wei ZhangDepartment of Hematology, Peking Union Medical College Hospital, Beijing, People’s Republic of ChinaCorrespondence[email protected]
View further author information
 show all
Pages 392-398 | Published online: 19 Mar 2019

References

  • Vose J, Armitage J, Weisenburger D, et al. International Peripheral T-cell and Natural Killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124–4130. doi: 10.1200/JCO.2008.16.4558
  • Shi Y. Current status and progress of lymphoma management in China. Int J Hematol. 2018;107:405–412. doi: 10.1007/s12185-018-2404-8
  • Wilhelm M, Smetak M, Reimer P, et al. First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation. Blood Cancer J. 2016;6:e452. doi: 10.1038/bcj.2016.63
  • D’Amore F, Relander T, Lauritzsen GF, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30:3093–3099. doi: 10.1200/JCO.2011.40.2719
  • Zhang J, Gao J, Li Y, et al. Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics. Thorac Cancer. 2015;6:534–538. doi: 10.1111/1759-7714.12247
  • Zhang P, Ouyang S, Wang J, et al. Levels of programmed death-1 and programmed death ligand-1 in the peripheral blood of patients with oral squamous cell carcinoma and its clinical implications. Hua Xi Kou Qiang Yi Xue Za Zhi. 2015;33:529–533.
  • Rossille D, Gressier M, Damotte D, et al. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-cell lymphoma: results from a French multicenter clinical trial. Leukemia. 2014;28:2367–2375. doi: 10.1038/leu.2014.137
  • Finkelmeier F, Canli Ö, Tal A, et al. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. Eur J Cancer. 2016;59:152–159. doi: 10.1016/j.ejca.2016.03.002
  • Okuma Y, Hosomi Y, Nakahara Y, et al. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer. Lung Cancer. 2017;104:1–6. doi: 10.1016/j.lungcan.2016.11.023
  • Nagato T, Ohkuri T, Ohara K, et al. Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy. Cancer Immunol Immunother. 2017;66(7):877–890. doi: 10.1007/s00262-017-1987-x
  • Bi XW, Wang H, Zhang WW, et al. PD-L1 is upregulated by EBV-driven LMP1 through NF-kappaB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma. J Hematol Oncol. 2016;9(1):109. doi: 10.1186/s13045-016-0341-7
  • Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program. 2009: 523–531. DOI:10.1182/asheducation-2009.1.523
  • A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329:987–994. doi: 10.1056/NEJM199309303291402
  • Carbone PP, Kaplan HS, Musshoff K, et al. Report of the committee on Hodgkin’s disease staging classification. Cancer Res. 1971;31:1860–1861.
  • Ruf M, Moch H, Schraml P. PD-l1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma. Int J Cancer. 2016;139:396–403. doi: 10.1002/ijc.30077
  • Grosso J, Horak CE, Inzunza D, et al. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538). J Clin Oncol. 2013;31(15):3016–3016.
  • Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other Features of the tumor immune microenvironment with response to anti–PD-1 therapy. Clin Cancer Res. 2014;20(19):5064–5074. doi: 10.1158/1078-0432.CCR-13-3271

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.